{"id":53340,"date":"2026-01-08T13:42:58","date_gmt":"2026-01-08T05:42:58","guid":{"rendered":"https:\/\/flcube.com\/?p=53340"},"modified":"2026-01-08T13:42:58","modified_gmt":"2026-01-08T05:42:58","slug":"sanofis-redemplo-wins-nmpa-approval-as-first-sirna-for-familial-chylomicronemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53340","title":{"rendered":"Sanofi&#8217;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia"},"content":{"rendered":"\n<p><strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong> announced that <strong>Redemplo (plozasiran sodium injection)<\/strong>, the world&#8217;s first <strong>small interfering RNA (siRNA) therapeutic targeting APOC3<\/strong>, has been <strong>approved by China&#8217;s National Medical Products Administration (NMPA)<\/strong> as an adjunct to diet to <strong>reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS)<\/strong>. The approval marks the <strong>first siRNA therapy for FCS<\/strong> in China, offering <strong>80% triglyceride reduction<\/strong> and <strong>convenient quarterly dosing<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-milestone\">Product &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Redemplo (plozasiran sodium injection)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sanofi (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved (06\u202fJan\u202f2026)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adjunct to diet for triglyceride reduction in adult FCS patients<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>siRNA targeting APOC3 mRNA<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>World&#8217;s first APOC3\u2011targeting siRNA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-efficacy-amp-safety-profile\">Clinical Efficacy &amp; Safety Profile<\/h2>\n\n\n\n<p><strong>Efficacy Results<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>80% reduction<\/strong> in fasting triglyceride levels from baseline<\/li>\n\n\n\n<li><strong>80% reduction<\/strong> in acute pancreatitis incidence vs. placebo<\/li>\n\n\n\n<li><strong>Convenient dosing<\/strong>: <strong>Four times per year<\/strong> (once every three months)<\/li>\n<\/ul>\n\n\n\n<p><strong>Safety Profile<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Overall adverse event risk <strong>no significant difference vs. placebo<\/strong><\/li>\n\n\n\n<li><strong>Lower rates<\/strong> of serious adverse events and treatment discontinuation vs. placebo<\/li>\n\n\n\n<li><strong>High patient compliance<\/strong> due to Q3M subcutaneous injection regimen<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-acquisition-history\">Market Context &amp; Acquisition History<\/h2>\n\n\n\n<p><strong>FCS Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare genetic disorder<\/strong> with severely elevated triglyceride levels<\/li>\n\n\n\n<li><strong>China Prevalence<\/strong>: <strong>~5,000\u20118,000<\/strong> diagnosed patients<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China severe hypertriglyceridemia market <strong>\u00a5800\u202fmillion<\/strong> (2025), growing at <strong>18% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Sanofi&#8217;s Strategic Moves<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>August\u202f1\u202f2025<\/strong>: Signed asset purchase agreement with <strong>Visirna Therapeutics<\/strong> (Arrowhead subsidiary) for Greater China rights<\/li>\n\n\n\n<li><strong>December\u202f2025<\/strong>: FDA granted <strong>Breakthrough Therapy Designation<\/strong> for <strong>severe hypertriglyceridemia (sHTG)<\/strong>, expanding treatment scope<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy\">Commercial Strategy<\/h2>\n\n\n\n<p><strong>Launch Timeline<\/strong>: Q2\u202f2026 via Sanofi\u2019s <strong>established rare disease infrastructure<\/strong> (1,200+ specialty pharmacies) in China.<\/p>\n\n\n\n<p><strong>Pricing Strategy<\/strong>: Projected <strong>\u00a5180,000\u2011220,000<\/strong> annual cost, with patient assistance program to reduce out\u2011of\u2011pocket burden.<\/p>\n\n\n\n<p><strong>Reimbursement Pathway<\/strong>: Targeting <strong>NRDL inclusion via rare disease priority review<\/strong> in 2027, which could triple patient access.<\/p>\n\n\n\n<p><strong>Manufacturing<\/strong>: Imported from Sanofi\u2019s Germany facility initially; tech transfer to Suzhou site planned for 2027\u20112028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage (China)<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Onpattro<\/strong><\/td><td>Alnylam<\/td><td>siRNA (TTR)<\/td><td>Marketed (different indication)<\/td><td>Not for FCS<\/td><\/tr><tr><td><strong>Volanesorsen<\/strong><\/td><td>Ionis<\/td><td>ASO (APOC3)<\/td><td>Not approved (safety concerns)<\/td><td>Injection weekly, thrombocytopenia risk<\/td><\/tr><tr><td><strong>Redemplo<\/strong><\/td><td><strong>Sanofi<\/strong><\/td><td>siRNA (APOC3)<\/td><td><strong>Approved<\/strong><\/td><td><strong>Q3M dosing, superior safety<\/strong><\/td><\/tr><tr><td><strong>Gemcabene<\/strong><\/td><td>Pfizer\/Lilly<\/td><td>ApoC\u2011III inhibitor<\/td><td>Phase\u202fIII<\/td><td>Small molecule, less potent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Redemplo&#8217;s Q3M dosing and clean safety profile provide clear competitive advantage.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China FCS Patients Treated<\/strong><\/td><td>1,200<\/td><td>2,500<\/td><td>4,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>60%<\/td><td>75%<\/td><td>85%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>216<\/td><td>450<\/td><td>756<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>88%<\/td><td>90%<\/td><td>91%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales Potential<\/strong>: <strong>\u00a51.8\u202fbillion<\/strong> (US$250\u202fmillion) by 2032, assuming sHTG indication expansion.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Redemplo&#8217;s commercial launch, market penetration, and revenue forecasts. Actual results may differ materially due to pricing negotiations, reimbursement approvals, and competitive responses.<strong>Future Prospects<\/strong><br>The acquisition of Cromsource by ClinChoice represents a significant milestone in the company&#8217;s global expansion strategy. By integrating Cromsource&#8217;s services and expertise, ClinChoice aims to enhance its service offerings and expand its reach in key markets. This strategic move positions ClinChoice to better support the growing demands of the biotech and pharma industries, contributing to the advancement of medical research and development on a global scale.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world&#8217;s first small interfering RNA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[867,15,147],"class_list":["post-53340","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-nasdaq-sny","tag-product-approvals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world&#039;s first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China&#039;s National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53340\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world&#039;s first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China&#039;s National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53340\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T05:42:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia\",\"datePublished\":\"2026-01-08T05:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340\"},\"wordCount\":507,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NASDAQ: SNY\",\"Product approvals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53340#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53340\",\"name\":\"Sanofi's Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-08T05:42:58+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world's first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China's National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53340\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53340#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world's first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China's National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53340","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia","og_description":"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world's first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China's National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.","og_url":"https:\/\/flcube.com\/?p=53340","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T05:42:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53340#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53340"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia","datePublished":"2026-01-08T05:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53340"},"wordCount":507,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NASDAQ: SNY","Product approvals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53340#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53340","url":"https:\/\/flcube.com\/?p=53340","name":"Sanofi's Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-08T05:42:58+00:00","description":"Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world's first small interfering RNA (siRNA) therapeutic targeting APOC3, has been approved by China's National Medical Products Administration (NMPA) as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). The approval marks the first siRNA therapy for FCS in China, offering 80% triglyceride reduction and convenient quarterly dosing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53340#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53340"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53340#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53340"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53340\/revisions"}],"predecessor-version":[{"id":53342,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53340\/revisions\/53342"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}